*Dose registered for erosive esophagitis and gastroesophageal reflux disease. iv.: Intravenous; NA: Nonavailable. Alex Mejia, MD, Department of Pharmacology and Experimental Therapeutics, Division ...

Broad-Spectrum Antiviral NV-387 Phase II Clinical Trial Responding to MPox Pandemic in Africa, Readying to Tackle Bird Flu ...